Connect with us

Medical Science

Huge spike in resting heart rate is a Sensitive indicator of COVID-19: Study

Srinagar, Dec 27: While temperature measurements are widely used for screening Covid-19 patients at the entrances of many office buildings or malls, a new study suggests that a huge spike in resting heart rate is a more sensitive indicator of the disease.


Physiological data from commercial wearables showed increased resting heart rate around symptoms onset date that was more severe for Covid-19, but present in milder form for flu as well, said the study published in the journal Patterns.


It’s surprising to see that many screening tests at building entrances are all temperature-based since a lot of people don’t develop a fever right away and there are so many things that cause fever other than COVID-19,’ said senior author Luca Foschini, Co-founder of US-based health and measurement company Evidation Health.


Covid-19: Huge spike in resting heart rate can be concerning
‘A huge spike in resting heart rate is a more sensitive indicator of Covid. And for people with activity trackers, you could ask them permission to share that information for screening purposes, just like taking a temperature reading.’


By analyzing Fitbit data and self-reported symptoms, the researchers analyzed trends in heart rate, step count, and symptom duration between patients with flu and those with Covid-19.


While both showed similar-looking spikes in resting heart rate and decreases in average step count, Covid-19 symptoms lasted longer and peaked later, said the study.


The findings confirmed that certain other symptoms are characteristic of Covid but not flu, like shortness of breath and coughing.


They also examined the impact of each illness on decreasing daily step count, finding that the impacts lasted much longer for Covid than for flu.


‘We used step count to measure the change in mobility because you don’t move as much when you’re sick,’ said Foschini.


‘Compared to their baseline, the number of steps didn’t go back to normal for people with COVID, even after three or four weeks.’


While data from wearables such as Fitbit can reveal a lot about these respiratory illnesses, the researchers said that it should be used as a general screening method, not a complete diagnostic tool.


What are the common symptoms?


Doctors and scientists are learning new things about this virus every day. So far, we know that COVID-19 may not cause any symptoms for some people.


You may carry the virus for 2 days or up to 2 weeks before you notice symptoms.


Some common symptoms that have been specifically linked to COVID-19 include:


-Shortness of breath
-A cough that gets more severe over time
-A low-grade fever that gradually increases in temperature


Less common symptoms include:

  • Repeated shaking with chills
  • Sore throat
  • Headache
  • Muscle aches and pains
  • Loss of taste or smell
  • A stuffy or runny nose
  • Gastrointestinal symptoms such as diarrhea, nausea, and vomiting
  • Discoloration of fingers or toes
    However, individuals with COVID-19 may have some, all, or none of the above symptoms.
    These symptoms may become more severe in some people. Call emergency medical services if you have or someone you care for has any of the following symptoms:
  • Trouble breathing
  • Blue lips or a blue face
  • Persistent pain or pressure in the chest
  • Excessive drowsiness
    (With inputs from IANS)

Continue Reading
Advertisement

Medical Science

AstraZeneca woes grow as Australia, Philippines, African Union curb COVID shots

(Asian News Hub) – Australia and the Philippines limited use of AstraZeneca’s COVID-19 vaccine, while the Africa Union dropped plans to buy the shot, dealing further blows to the company’s hopes to deliver a vaccine for the world.

The vaccine – developed with Oxford University and considered a frontrunner in the global vaccine race – has been plagued by safety concerns and supply problems since Phase III trial results were published in December, with Indonesia the latest country forced to seek doses from other vaccine developers.

The Philippines suspended the use of AstraZeneca shots for people below 60 after Europe’s regulator said on Wednesday it found rare cases of blood clots among some adult recipients although the vaccine’s advantages still outweighed its risks.

Australia recommended people under 50 should get Pfizer’s COVID-19 vaccine in preference to AstraZeneca’s, a policy shift that it warned would hold up its inoculation campaign.

The African Union is exploring options with Johnson & Johnson having dropped plans to buy AstraZeneca’s vaccine from India’s Serum Institute, the head of the Africa Centres for Disease Control and Prevention told reporters.

AstraZeneca’s shot is sold at cost, for a few dollars a dose. It is by far the cheapest and most high-volume launched so far, and has none of the extreme refrigeration requirements of some other COVID-19 vaccines, making it likely to be the mainstay of many vaccination programmes in the developing world.

But more than a dozen countries have at one time suspended or partially suspended use of the shot, first on concerns about efficacy in older people, and now on worries about rare side effects in younger people.

That, coupled with production setbacks, will delay the rollout of vaccines across the globe as governments scramble to find alternatives to tame the pandemic which has killed more than 3 million.

Reuters

Continue Reading

Medical Science

A third of COVID survivors suffer neurological or mental disorders: study

(Asian News Hub) – One in three COVID-19 survivors in a study of more than 230,000 mostly American patients were diagnosed with a brain or psychiatric disorder within six months, suggesting the pandemic could lead to a wave of mental and neurological problems, scientists said.

Researchers who conducted the analysis said it was not clear how the virus was linked to psychiatric conditions such as anxiety and depression, but that these were the most common diagnoses among the 14 disorders they looked at.

Post-COVID cases of stroke, dementia and other neurological disorders were rarer, the researchers said, but were still significant, especially in those who had severe COVID-19.

“Although the individual risks for most disorders are small, the effect across the whole population may be substantial,” said Paul Harrison, a professor of psychiatry at Oxford University who co-led the work.

Max Taquet, also an Oxford psychiatrist who worked with Harrison, noted that the study was not able to examine the biological or psychological mechanisms involved, but said urgent research is needed to identify these “with a view to preventing or treating them”.

Health experts are increasingly concerned by evidence of higher risks of brain and mental health disorders among COVID-19 survivors.

A previous study by the same researchers found last year that 20% of COVID-19 survivors were diagnosed with a psychiatric disorder within three months.

The new findings, published in the Lancet Psychiatry journal, analysed health records of 236,379 COVID-19 patients, mostly from the United States, and found 34% had been diagnosed with neurological or psychiatric illnesses within six months.

The disorders were significantly more common in COVID-19 patients than in comparison groups of people who recovered from flu or other respiratory infections over the same time period, the scientists said, suggesting COVID-19 had a specific impact.

Anxiety, at 17%, and mood disorders, at 14%, were the most common, and did not appear to be related to how mild or severe the patient’s COVID-19 infection had been.

Among those who had been admitted to intensive care with severe COVID-19 however, 7% had a stroke within six months, and almost 2% were diagnosed with dementia.

Independent experts said the findings were worrying.

“This is a very important paper. It confirms beyond any reasonable doubt that COVID-19 affects both brain and mind in equal measure,” said Simon Wessely, chair of psychiatry at King’s College London.

“The impact COVID-19 is having on individuals’ mental health can be severe,” said Lea Milligan, chief executive of the MQ Mental Health research charity. “This is contributing to the already rising levels of mental illness and requires further, urgent research.”

Reuters

Continue Reading

Medical Science

COVID-19 situation not good: AIIMS chief

(Asian News Hub) – Amid the rapidly increasing cases of COVID-19 across India, AIIMS Chief Randeep Guleria on Friday (April 2) said that a mini lockdown may be required to get a grip on the deteriorating situation.

Guleria said that the situation in the country with regard to the COVID-19 pandemic is quite worrying as the cases continue to mount steadily, especially in the last few days.

He cautioned that maintaining social distancing that is, keeping six-feet away from each other, is required even for those who have been inoculated against the virus. He also strongly suggested people to wear masks at public places.

The AIIMS chief attributed the sharp spike in the number of cases to the negligence of people, mainly due to public gatherings.

“Negligence leads to illness,” said Guleria in a message to the people.

He said that the country needs about 200 crore doses to vaccinate the entire population.

Although recovery rate among children has been found high, said Guleria, it is a cause for concern that many children are contracting the infection.

He also emphasized on the need to create containment zones, so that the spread of the virus could be kept in check.

Continue Reading

Trending